US20010001126A1 - Implantable electric heart defibrillator with attenuation of the pain resulting from the electric shock - Google Patents

Implantable electric heart defibrillator with attenuation of the pain resulting from the electric shock Download PDF

Info

Publication number
US20010001126A1
US20010001126A1 US09/732,320 US73232000A US2001001126A1 US 20010001126 A1 US20010001126 A1 US 20010001126A1 US 73232000 A US73232000 A US 73232000A US 2001001126 A1 US2001001126 A1 US 2001001126A1
Authority
US
United States
Prior art keywords
heart
shock
electrically
defibrillating
arrhythmia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/732,320
Inventor
Leonardo Cammilli
Gino Grassi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US09/732,320 priority Critical patent/US20010001126A1/en
Publication of US20010001126A1 publication Critical patent/US20010001126A1/en
Priority to US10/357,833 priority patent/US20030120312A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36071Pain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/38Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
    • A61N1/39Heart defibrillators
    • A61N1/3956Implantable devices for applying electric shocks to the heart, e.g. for cardioversion
    • A61N1/3962Implantable devices for applying electric shocks to the heart, e.g. for cardioversion in combination with another heart therapy
    • A61N1/39624Pain reduction therapy

Definitions

  • the present invention concerns a heart defibrillator and a method for its operation.
  • the invention has been developed with particular attention to its possible application to so-called heart defibrillators.
  • the invention is, however applicable to defibrillators in generally and should not therefore be understood as limited to the specific field of use referred to below in the present description.
  • Ventricular fibrillation consists of chaotic, asynchronous and fractional activity of the ventricles.
  • all of the cells contract independently and not synchronously, with the final result that the pumping function of the heart is lost and circulatory arrest occurs; without intervention, the patient dies.
  • VVT malignant ventricular tachycardia
  • a stimulation system with anti-tachycardia programs (with burst and premature extra-stimulation capabilities and the like) which are used as a first approach for the cardioversion of MVT is fitted, together with the defibrillation system, in the same device.
  • the system can deliver an electric shock which has a greater probability of interrupting the MVT but which usually has less energy than for ventricular fibrillation.
  • ICDs implantable cardioverter defibrillators
  • ICDs The implantation of ICDs is currently the only safe means of ensuring the survival of patients affected by these arrhythmias which are otherwise fatal.
  • the shock is delivered about 10 seconds after ventricular fibrillation is recognized; this leads to circulatory arrest with loss of flow of oxygenated blood to the brain so that, after 5-6 seconds, the patient loses consciousness, falling to the ground if he is standing up.
  • the delay in the delivery of the shock is necessary in order to confirm the diagnosis of ventricular fibrillation and to charge the capacitor which serves to store the energy for the delivery of the shock.
  • the delay is also necessary in order to deliver the shock when the patient is unconscious so that he does not feel the pain of the discharge. In some cases of younger patients who are still conscious when the discharge is delivered, the sensation of pain is in fact so strong and distressing that some patients have asked for the ICD to be removed.
  • Atrial fibrillation is an arrhythmia which causes disappearance of the atrial contractions which are replaced by fibrillation, that is, by uncoordinated activity which nullifies the pumping effect of normal contraction. It is compatible with life since blood circulation is maintained, although with a reduction in the cardiac range.
  • Atrial fibrillation causes stagnation of the blood in the atrium which favors the formation of a thromboembolism which, in time, puts the patient's life at risk.
  • the irregularity of the ventricular response may set off dangerous ventricular tachycardia. This arrhythmia can be treated pharmacologically but insensitivity to the drugs is often encountered.
  • Another possibility is electric cardioversion which consists of the application of an electric shock similar to ventricular defibrillation but with lower discharge energy.
  • the implanted atrial defibrillator technique was proposed and implemented in order to deliver a shock directly to the appropriate locations of the heart cavity at the onset of the arrhythmia.
  • the need to attenuate or cancel out the pain caused by the discharge which, in this case, is applied to conscious patients who have difficulty in tolerating it, becomes fundamental.
  • the object of the invention is to produce an implantable atrial or ventricular defibrillator which allows patients to have a less traumatic life, by means of the characteristics which will be described below.
  • this invention is a method of electrically defibrillating a heart, comprising sensing a heart arrhythmia; stimulating the spinal column to produce an analgesic effect; and delivering an electrical shock to defibrillate the heart.
  • the method may also include stimulating the spinal column by saturating the pathways of the pain caused by the shock by the “gate control” method.
  • the step of delivering the electrical shock is synchronized with the patient's QRS.
  • a blanking circuit also may be provided. The blanking circuit generates a signal which can protect the other circuits from the electrical shock, and is activated prior to the delivery of the shock and terminated after delivery of the shock.
  • the arrhythmia may be a ventricular fibrillation or atrial arrhythmia.
  • the step of sensing the arrhythmia may include sensing within 2 seconds from the start of the arrhythmia an electrical signal from the heart having an average frequency greater than 280-300 beats per minute with irregularities in period and amplitude and sensing a stoppage of pumping of the heart.
  • the step of delivering the electrical shock may include delivering the electrical shock no longer than three seconds after sensing the arrhythmia.
  • the step of stimulating the spinal column to produce an analgesic effect may include infusing an analgesic drug or electrically stimulating a nerve immediately upon sensing the arrhythmia.
  • the step of sensing the arrhythmia preferably allows sufficient time to verify the stability of the arrhythmia.
  • the step of delivering the electrical shock may take up to one minute from sensing the arrhythmia, and the electrical shock may be between 1 and 10 Joules.
  • the step of stimulating the spinal column preferably occurs at least two seconds before the electrical shock.
  • the arrhythmia may be ventricular tachycardia.
  • the step of sensing the arrhythmia may include sensing an electrical signal from the heart beating up to 300 beats per minutes, wherein the beats have substantially constant frequency and amplitude, and further sensing an attenuated and/or irregular blood flow without stoppage of the heart.
  • a pacing electrical stimulus may be applied as a first treatment and, if this is unsuccessful after a programmed number of attempts, a low energy cardioversion shock may be delivered.
  • the step of stimulating the spinal column may include infusing an analgesic drug with immediate effect.
  • the step of sensing the arrhythmia may include sensing the arrhythmia through electrical, mechanical, and electromechanical impulses.
  • FIG. 1 is a block diagram showing the elements of the defibrillating system
  • FIG. 2 is a block diagram describing an embodiment of the system in greater detail.
  • FIG. 3 illustrates the time sequences of the interventions for ventricular fibrillation of the various components which are characteristic of the proposed system.
  • FIG. 4 illustrates the time sequences of the interventions for atrial fibrillation of the various components which are characteristic of the proposed system.
  • the sequence of operation is as follows.
  • the circuit B recognizes the presence of fibrillation by means of the sensors A within a time no longer than 2 sec.
  • a signal starts the nerve stimulator (or the infusion pump) C which produces the gate effect in the nervous system involved in receiving the expected pain signals, by means of the spinal electrodes (or the infusion catheter) D.
  • the quick shock-energy generator E charges the capacitor which stores the energy within a time less than or equal to 3 sec. If the circuit B confirms fibrillation, the discharge is delivered at a time no longer than 4-5 sec. after recognition.
  • the various components of the proposed system can be formed by solutions already existing in various implantable defibrillator models and spinal-chord nerve stimulators (or drug infusers) which have already been produced.
  • ventricular fibrillation with regard to its electrical component has now been established and it is proposed herein to supplement it by means of a second sensor, for example, a mechanical sensor so as to be able to recognize the type of arrhythmia with certainty within a very short time.
  • the stimulation parameters of nerve stimuli which are generally used to treat long-term pains, have to be adapted to the need to prevent the propagation of a pain which is expected, sudden and of short duration, at least with regard to its cause. Any infuser must be designed to deliver an analgesic drug with immediate effect.
  • the generator and supplier of the electric shock must be put into operation in a very short time as is, however, already provided for in the latest generations of defibrillators.
  • the entire device which forms the proposed system can preferably be fitted in a single implantable container although this is not functionally necessary as long as the various functions are interconnected electrically or electromagnetically.
  • the block diagram of FIG. 2 will be considered in order to describe a possible embodiment of the system in greater detail.
  • the sensors 1 and 2 constitute the arrhythmia detection and recognition system.
  • the electric sensor 1 analyses the electrical signal of the heart which enables the presence of ventricular tachycardia to be distinguished from ventricular fibrillation, by considering, for example, the aroma frequency of the complexes and the regularity of the period and amplitude of the heart signals.
  • the electrical diagnoses which, in some cases, could be uncertain, can be confirmed with the use of a mechanical (or electromechanical) signal, for measuring, for example, systolic pressure, which is practically zero in ventricular fibrillation, or contractility, which is easily detectable by means of recently-proposed implantable transducers, or by rheography, or heart noise.
  • a mechanical (or electromechanical) signal for measuring, for example, systolic pressure, which is practically zero in ventricular fibrillation, or contractility, which is easily detectable by means of recently-proposed implantable transducers, or by rheography, or heart noise.
  • the algorithm which can be implemented with systems of this type enables ventricular tachycardia to be distinguished from ventricular fibrillation; in fact in ventricular tachycardia, neither the pressure nor the contractility become zero, although their values are much lower than the normal sine function and amplitude and frequency may be irregular; with ventricular fibrillation, on the other hand, the pressure and contractility fall practically and abruptly to zero and the heart noise is almost non-existent.
  • the circuit represented by block 3 is provided for processing the data obtained by 1 and 2 by an algorithm which, as stated above, recognizes the type of arrhythmia, providing a signal indicating the presence of ventricular fibrillation or ventricular tachycardia to downstream circuits. If the arrhythmia recognized is ventricular fibrillation the proposed system starts block 4 and block 8 together.
  • block 4 represents, by way of non-limiting example, the nerve stimulator assembly the stimulating electrodes 6 of which are inserted in the spinal chord in positions in which the closure of the gate will cancel out the transmission of the pain signals coming from the heart region and from the surrounding muscles.
  • the drug infuser may be used in similar manner.
  • the functional characteristics of block 4 are known to experts in the art and are programmed in a manner such that the nerve stimulation effect is immediate (usually from 0.5 to 1 sec. delay) and effective for the region affected.
  • Block 8 represents the system for the storage of the shock energy, which consists in charging a capacitor such as that normally used in ICDs, contained in block 9 .
  • the main characteristic of block 8 is that it can charge the capacitor, which usually has a capacitance of between 80 and 180 ⁇ F, to the maximum energy of 25-30 J within a time less than or equal to 3 seconds.
  • the short charging time is important for the purposes of the invention; it has already been achieved in the design of implantable defibrillators currently in production.
  • the circuit 5 confirms the presence of ventricular fibrillation about 4-5 seconds after the recognition effected by 3 .
  • the circuit of block 9 provides for the emission of a shock with the electrical characteristics (wave-form, duration, etc.) required and programmed by the operator.
  • the shock is delivered by means of the electrode system (endocavitary or epicardial) 11 which comprises the defibrillation electrodes and those for the pre-selected programmed stimulation for any ventricular tachycardia.
  • Block 10 which comprises a programmable anti-tachycardia stimulator which can deliver the pre-selected stimulation program for tachyarrhythmia and implement the algorithms normally used for this treatment such as, for example, burst, premature extra-stimuli, overdrive.
  • Block 10 is also capable of delivering a normal stimulation in the event of stoppage or asystole after defibrillation or cardioversion so as to promote the re-establishment of a possible sinusoidal rhythm.
  • the programmed stimulation is delivered by means of the electrode system 11 .
  • Block 7 consists of a circuit provided for creating blanking which electrically excludes both the anti-arrhythmic pacemaker 10 and the nerve stimulator 4 from normal operation in order, as far as possible, to protect the electronic circuits from the shock of the defibrillation signal which could damage them because of its high energy.
  • the blanking signal is applied for a time slightly greater than the total duration of the shock pulse; a duration of about 20-30 mseconds, starting from the leading edge of the shock itself or a few mseconds earlier, will normally suffice.
  • the electrode systems 1 , 2 and 6 must be protected from discharges greater than about 20 Volts, for example, by means of semiconductor devices well known in electronics.
  • FIG. 3A describes operation during persistent ventricular fibrillation.
  • Recognition system 3 notices the ventricular fibrillation at time 20 and immediately starts nerve stimulator 4 and the charging of capacitor 8 .
  • checking system 5 checks that arrhythmia is present.
  • Capacitor 8 will already be charged at time 21 .
  • blanking circuit 7 protects the circuits with a signal of duration 24 which is greater than discharge time 22 , stimulator 4 also being prevented for the period 23 .
  • circuit 9 delivers shock 22 which should interrupt the ventricular fibrillation. Nerve stimulator 4 will continue to protect the patient from the pain for a programmable period which may be as long as a few minutes.
  • FIG. 3B shows a case of ventricular fibrillation which disappears naturally at a time earlier than that programmed for the discharge. After the start at time 25 which triggers stimulator 4 and charging circuit 8 , the ventricular fibrillation disappears at time 26 , and all of the circuits are reset.
  • FIG. 3C gives an example in which ventricular tachycardia occurs.
  • circuit 3 recognizes the type of arrhythmia as ventricular tachycardia and activates anti-arrhythmic stimulator circuit 10 which starts to deliver stimuli in accordance with the programmed algorithms.
  • circuit 3 will start both spinal cord stimulator (SCS) generator 4 and the capacitor-charging circuit 8 at time 28 up to the time at which the programmed energy 25 is reached.
  • SCS spinal cord stimulator
  • blanking signal 31 will start and will protect the circuits of the system during the shock for period 34 .
  • the delivery of shock 30 will cancel out the arrhythmia and the system will be reset.
  • FIG. 4 shows the sequence of operation of the various blocks in the case of atrial fibrillation. Also this refers to FIG. 2.
  • Recognition system 3 detects atrial fibrillation at time 40 .
  • the charging of the capacitor by block 8 is started, the programmed energy being reached after time 46 which may even be one minute.
  • nerve stimulator 4 starts the stimulation.
  • Checking system 5 checks the existence of atrial fibrillation.
  • the blocking of the blanking unit is switched on for time 45 which lasts until a few hundred milliseconds after the shock.
  • the circuits of blocks 3 , 4 and 5 are prevented and/or protected against the shock energy which is propagated through the patient's body.
  • the cardioversion electric shock is delivered and is synchronized with the patient's QRS by blocks 3 and 5 . Circuits 3 and 5 then become active again in order to monitor the patient and nerve stimulator 4 continues in accordance with the program setting.

Abstract

An implantable electrical heart defibrillation system for both ventricle and atrium is proposed and is characterized in that it acts in a manner such as:
to diagnose the type of arrhythmia within a maximum time of 2 seconds from the onset of the arrhythmia;
to deliver the therapeutic shock by electrodes implanted in the region to be defibrillated no more than 4-5 seconds after the recognition of the arrhythmia, if it is ventricular fibrillation, so that the patient does not loose consciousness;
immediately after the onset of the arrhythmia and before the defibrillation shock is delivered, to prevent the conduction of neural pain signals coming from the region in which the electric shock acts, by means of nerve stimulation by a catheter inserted in the spinal column, utilizing the gate effect, or by the perfusion of a drug with immediate analgesic effect by means of an infusion pump and a catheter positioned in the region affected by the pain signals.
This system enables defibrillation or conversion to be carried out with the patient conscious and within a sufficiently short time to be able to use low shock energy, and with prevention of the consequent painful shock.
This considerably improves the quality of life of the patient who is no longer subject to loss of consciousness during ventricular fibrillation and does not feel the pain during the electric shock.

Description

    FIELD OF THE INVENTION
  • 1. The present invention concerns a heart defibrillator and a method for its operation.
  • 2. The invention has been developed with particular attention to its possible application to so-called heart defibrillators. The invention is, however applicable to defibrillators in generally and should not therefore be understood as limited to the specific field of use referred to below in the present description.
  • BACKGROUND OF THE INVENTION
  • 3. Most unexpected heart deaths are due to ventricular fibrillation in patients both with and without coronary disease. Ventricular fibrillation consists of chaotic, asynchronous and fractional activity of the ventricles. In a heart which has started the ventricular fibrillation process, all of the cells contract independently and not synchronously, with the final result that the pumping function of the heart is lost and circulatory arrest occurs; without intervention, the patient dies.
  • 4. The only way of intervening is by electric heart defibrillation. This method, which was implemented successfully as early as 1908, came back into clinical practice around the 1940s and has been used increasingly since then. External defibrillation is achieved by applying to the patient's chest two plates by means of which an electric shock is transmitted. In recent years, implantable electric defibrillators have been designed and produced and these apply the electric shock directly to the heart wall, the shock being delivered automatically as soon as ventricular fibrillation is recognized by the circuits.
  • 5. It should also be noted that malignant ventricular tachycardia (MVT), which is usually a precursor of ventricular fibrillation, can also be treated by electric cardioversion. A stimulation system with anti-tachycardia programs (with burst and premature extra-stimulation capabilities and the like) which are used as a first approach for the cardioversion of MVT is fitted, together with the defibrillation system, in the same device. In serious cases which are insensitive to anti-arrhythmic stimulation, when a certain number of attempts with this program have been found ineffective, the system can deliver an electric shock which has a greater probability of interrupting the MVT but which usually has less energy than for ventricular fibrillation.
  • 6. The implantation of these devices (ICDs—implantable cardioverter defibrillators) started in 1980 and, since the 1990s, has increased notably because of the considerable technological progress and the increased ease of implantation due, in particular, to the use of catheter-electrodes which are introduced by a peripheral venous route in the same manner as for the implantation of pacemakers.
  • 7. The implantation of ICDs is currently the only safe means of ensuring the survival of patients affected by these arrhythmias which are otherwise fatal.
  • 8. There are, however, considerable problems, including:
  • 9. a) the harmful nature of the electric shock which, with the energy of about 30 Joules currently used, damages the mitochondrial structures of the cells, and
  • 10. b) the fact that the life of the patient wearing the ICD is rendered traumatic by the loss of consciousness which occurs in the presence of ventricular fibrillation and hence of defibrillation, even though this saves the patient's life.
  • 11. In fact, the shock is delivered about 10 seconds after ventricular fibrillation is recognized; this leads to circulatory arrest with loss of flow of oxygenated blood to the brain so that, after 5-6 seconds, the patient loses consciousness, falling to the ground if he is standing up.
  • 12. The delay in the delivery of the shock is necessary in order to confirm the diagnosis of ventricular fibrillation and to charge the capacitor which serves to store the energy for the delivery of the shock.
  • 13. The delay is also necessary in order to deliver the shock when the patient is unconscious so that he does not feel the pain of the discharge. In some cases of younger patients who are still conscious when the discharge is delivered, the sensation of pain is in fact so strong and distressing that some patients have asked for the ICD to be removed.
  • 14. The situation in which it is necessary to interrupt MVT by means of the shock should also be considered; in fact the delivery of the shock takes place when the patient is fully conscious since, although MVT is disabling, it does not cause loss of consciousness. In these cases, the pain complained of by the patient which, amongst other things, is sudden, is very great, although it is not of long duration.
  • 15. In any case, even in patients who do not feel the shock, their existence becomes so traumatic with the continual fear and expectation of crises accompanied by loss of consciousness that they sometimes prefer the risk of death.
  • 16. A condition which is similar to ventricular fibrillation as a physiological phenomenon, although it does not involve an immediate danger of death of the patient will now also be considered.
  • 17. Atrial fibrillation (AF) is an arrhythmia which causes disappearance of the atrial contractions which are replaced by fibrillation, that is, by uncoordinated activity which nullifies the pumping effect of normal contraction. It is compatible with life since blood circulation is maintained, although with a reduction in the cardiac range.
  • 18. However, atrial fibrillation causes stagnation of the blood in the atrium which favors the formation of a thromboembolism which, in time, puts the patient's life at risk. Moreover, the irregularity of the ventricular response may set off dangerous ventricular tachycardia. This arrhythmia can be treated pharmacologically but insensitivity to the drugs is often encountered.
  • 19. Another possibility is electric cardioversion which consists of the application of an electric shock similar to ventricular defibrillation but with lower discharge energy. A couple of years ago, the implanted atrial defibrillator technique was proposed and implemented in order to deliver a shock directly to the appropriate locations of the heart cavity at the onset of the arrhythmia. For this treatment, the need to attenuate or cancel out the pain caused by the discharge which, in this case, is applied to conscious patients who have difficulty in tolerating it, becomes fundamental.
  • 20. It can be seen from the foregoing description that an ability to prevent the pain signals from being perceived by the patient is very important.
  • SUMMARY OF THE INVENTION
  • 21. The object of the invention is to produce an implantable atrial or ventricular defibrillator which allows patients to have a less traumatic life, by means of the characteristics which will be described below.
  • 22. In one aspect, this invention is a method of electrically defibrillating a heart, comprising sensing a heart arrhythmia; stimulating the spinal column to produce an analgesic effect; and delivering an electrical shock to defibrillate the heart. The method may also include stimulating the spinal column by saturating the pathways of the pain caused by the shock by the “gate control” method. Preferably, the step of delivering the electrical shock is synchronized with the patient's QRS. A blanking circuit also may be provided. The blanking circuit generates a signal which can protect the other circuits from the electrical shock, and is activated prior to the delivery of the shock and terminated after delivery of the shock. The arrhythmia may be a ventricular fibrillation or atrial arrhythmia.
  • 23. The step of sensing the arrhythmia may include sensing within 2 seconds from the start of the arrhythmia an electrical signal from the heart having an average frequency greater than 280-300 beats per minute with irregularities in period and amplitude and sensing a stoppage of pumping of the heart.
  • 24. The step of delivering the electrical shock may include delivering the electrical shock no longer than three seconds after sensing the arrhythmia. The step of stimulating the spinal column to produce an analgesic effect may include infusing an analgesic drug or electrically stimulating a nerve immediately upon sensing the arrhythmia.
  • 25. The step of sensing the arrhythmia preferably allows sufficient time to verify the stability of the arrhythmia. The step of delivering the electrical shock may take up to one minute from sensing the arrhythmia, and the electrical shock may be between 1 and 10 Joules. The step of stimulating the spinal column preferably occurs at least two seconds before the electrical shock.
  • 26. Alternatively, the arrhythmia may be ventricular tachycardia. The step of sensing the arrhythmia may include sensing an electrical signal from the heart beating up to 300 beats per minutes, wherein the beats have substantially constant frequency and amplitude, and further sensing an attenuated and/or irregular blood flow without stoppage of the heart. A pacing electrical stimulus may be applied as a first treatment and, if this is unsuccessful after a programmed number of attempts, a low energy cardioversion shock may be delivered.
  • 27. The step of stimulating the spinal column may include infusing an analgesic drug with immediate effect. The step of sensing the arrhythmia may include sensing the arrhythmia through electrical, mechanical, and electromechanical impulses.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • 28.FIG. 1 is a block diagram showing the elements of the defibrillating system
  • 29.FIG. 2 is a block diagram describing an embodiment of the system in greater detail.
  • 30.FIG. 3 illustrates the time sequences of the interventions for ventricular fibrillation of the various components which are characteristic of the proposed system.
  • 31.FIG. 4 illustrates the time sequences of the interventions for atrial fibrillation of the various components which are characteristic of the proposed system.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • 32. First of all, the case of ventricular fibrillation will be considered; the following solutions are proposed:
  • 33. a) to make a sure diagnosis within the first 1-2 seconds of the start of the arrhythmia,
  • 34. b) to deliver the electric shock no more than 3-4 seconds after the recognition of the ventricular fibrillation so as to start the shock when the patient is conscious and with less energy than is currently used because of the earliness of the intervention, and
  • 35. c) in order to be able to operate as in b), to prevent the patient's nervous system from receiving the pain stimulus due to the electric shock and to the abrupt contraction of the adjacent muscles. This can be achieved, for example, by the insertion of electrodes in the spinal column, the electrodes being connected to a nerve stimulator which will saturate the pain-conduction pathways (gate effect), preventing the pain from being perceived by the patient or, in any case, causing it to arrive greatly attenuated. The same result can also be achieved, for example, by means of an infusion pump which can send a drug which has an immediate effect (e.g. a recently investigated drug, conopeptide, with effectiveness 100 times greater than morphine) to the appropriate sites of the nerve endings affected by the shock in order to cancel out the perception of the pain.
  • 36. The instrument for implementing the system proposed is made up essentially as shown by the simplified block diagram which shows its main components.
  • 37. In FIG. 1, the various blocks represent:
  • 38. A sensors for detecting fibrillation,
  • 39. B fibrillation or tachycardia recognition circuit,
  • 40. C programmable nerve stimulator or analgesic drug infusion pump,
  • 41. D neural electrode system for the spinal column, or catheter for the infusion of the analgesic drug,
  • 42. E quickly prepared electric-shock generator, and
  • 43. F defibrillation electrode system.
  • 44. The sequence of operation is as follows. The circuit B recognizes the presence of fibrillation by means of the sensors A within a time no longer than 2 sec. When recognition has taken place, a signal starts the nerve stimulator (or the infusion pump) C which produces the gate effect in the nervous system involved in receiving the expected pain signals, by means of the spinal electrodes (or the infusion catheter) D. At the same time, the quick shock-energy generator E charges the capacitor which stores the energy within a time less than or equal to 3 sec. If the circuit B confirms fibrillation, the discharge is delivered at a time no longer than 4-5 sec. after recognition.
  • 45. The solutions set out in points a), b) and c) described above are thus achieved:
  • 46. quick recognition of ventricular fibrillation;
  • 47. immediate saturation of the pain-conduction pathways; and
  • 48. defibrillation at times close to the onset of the arrhythmia, within the first 5 seconds.
  • 49. The various components of the proposed system can be formed by solutions already existing in various implantable defibrillator models and spinal-chord nerve stimulators (or drug infusers) which have already been produced.
  • 50. The detection of ventricular fibrillation with regard to its electrical component has now been established and it is proposed herein to supplement it by means of a second sensor, for example, a mechanical sensor so as to be able to recognize the type of arrhythmia with certainty within a very short time. The stimulation parameters of nerve stimuli, which are generally used to treat long-term pains, have to be adapted to the need to prevent the propagation of a pain which is expected, sudden and of short duration, at least with regard to its cause. Any infuser must be designed to deliver an analgesic drug with immediate effect. The generator and supplier of the electric shock must be put into operation in a very short time as is, however, already provided for in the latest generations of defibrillators. Naturally, the entire device which forms the proposed system can preferably be fitted in a single implantable container although this is not functionally necessary as long as the various functions are interconnected electrically or electromagnetically.
  • 51. The block diagram of FIG. 2 will be considered in order to describe a possible embodiment of the system in greater detail. The sensors 1 and 2 constitute the arrhythmia detection and recognition system. The electric sensor 1 analyses the electrical signal of the heart which enables the presence of ventricular tachycardia to be distinguished from ventricular fibrillation, by considering, for example, the aroma frequency of the complexes and the regularity of the period and amplitude of the heart signals. The electrical diagnoses which, in some cases, could be uncertain, can be confirmed with the use of a mechanical (or electromechanical) signal, for measuring, for example, systolic pressure, which is practically zero in ventricular fibrillation, or contractility, which is easily detectable by means of recently-proposed implantable transducers, or by rheography, or heart noise. Reference may be made, for example, to the documents EP-A-0 515 319, EP-A-0 582 162, EP-A-0 655 260, EP-A-0 770 406 and EP-A-0 778 049.
  • 52. The algorithm which can be implemented with systems of this type enables ventricular tachycardia to be distinguished from ventricular fibrillation; in fact in ventricular tachycardia, neither the pressure nor the contractility become zero, although their values are much lower than the normal sine function and amplitude and frequency may be irregular; with ventricular fibrillation, on the other hand, the pressure and contractility fall practically and abruptly to zero and the heart noise is almost non-existent.
  • 53. The circuit represented by block 3 is provided for processing the data obtained by 1 and 2 by an algorithm which, as stated above, recognizes the type of arrhythmia, providing a signal indicating the presence of ventricular fibrillation or ventricular tachycardia to downstream circuits. If the arrhythmia recognized is ventricular fibrillation the proposed system starts block 4 and block 8 together.
  • 54. In this embodiment, block 4 represents, by way of non-limiting example, the nerve stimulator assembly the stimulating electrodes 6 of which are inserted in the spinal chord in positions in which the closure of the gate will cancel out the transmission of the pain signals coming from the heart region and from the surrounding muscles. The drug infuser may be used in similar manner. The functional characteristics of block 4 are known to experts in the art and are programmed in a manner such that the nerve stimulation effect is immediate (usually from 0.5 to 1 sec. delay) and effective for the region affected.
  • 55. Block 8 represents the system for the storage of the shock energy, which consists in charging a capacitor such as that normally used in ICDs, contained in block 9. The main characteristic of block 8 is that it can charge the capacitor, which usually has a capacitance of between 80 and 180 μF, to the maximum energy of 25-30 J within a time less than or equal to 3 seconds. The short charging time is important for the purposes of the invention; it has already been achieved in the design of implantable defibrillators currently in production.
  • 56. The circuit 5 confirms the presence of ventricular fibrillation about 4-5 seconds after the recognition effected by 3. In this case, the circuit of block 9 provides for the emission of a shock with the electrical characteristics (wave-form, duration, etc.) required and programmed by the operator. The shock is delivered by means of the electrode system (endocavitary or epicardial) 11 which comprises the defibrillation electrodes and those for the pre-selected programmed stimulation for any ventricular tachycardia.
  • 57. In fact, if the arrhythmia is recognized as ventricular tachycardia, a signal is sent to block 10 which comprises a programmable anti-tachycardia stimulator which can deliver the pre-selected stimulation program for tachyarrhythmia and implement the algorithms normally used for this treatment such as, for example, burst, premature extra-stimuli, overdrive. Block 10 is also capable of delivering a normal stimulation in the event of stoppage or asystole after defibrillation or cardioversion so as to promote the re-establishment of a possible sinusoidal rhythm. The programmed stimulation is delivered by means of the electrode system 11.
  • 58. Block 7 consists of a circuit provided for creating blanking which electrically excludes both the anti-arrhythmic pacemaker 10 and the nerve stimulator 4 from normal operation in order, as far as possible, to protect the electronic circuits from the shock of the defibrillation signal which could damage them because of its high energy. The blanking signal is applied for a time slightly greater than the total duration of the shock pulse; a duration of about 20-30 mseconds, starting from the leading edge of the shock itself or a few mseconds earlier, will normally suffice. For the same reason and as is normally the case, the electrode systems 1, 2 and 6 must be protected from discharges greater than about 20 Volts, for example, by means of semiconductor devices well known in electronics.
  • 59. The system proposed up to now can also be used with a few modifications in the case of atrial fibrillations. In this case, there is no need for early intervention, since this arrhythmia is disabling but not fatal. It is, however, important to try to prevent the painful sensation caused by the electric shock since this will take place when the patient is conscious. In the case of atrial cardioversion, the difference factors also render the production of the cardioverter easier and less critical. The energy required for atrial cardioversion is much lower than that required for ventricular defibrillation; normally from 1 to 10 Joules suffices. The charging of the capacitor for the shock can take place over longer periods, thus requiring a lower charge-generator power. To prevent pro-arrhythmic effects which could lead to ventricular fibrillation owing to the delivery of the shock in the period of ventricular vulnerability, the shock is synchronized with the patient's QRS.
  • 60. In view of the similarities between the two defibrillation methods, it is thus possible to design a single device which can be programmed with the two different algorithms, the sole change in the hardware being in the electrode system 11 of FIG. 2. The time sequences of the interventions of the various components which are characteristic of the proposed system are shown schematically in FIG. 3 for ventricular fibrillation and in FIG. 4 for atrial fibrillation.
  • 61.FIG. 3A describes operation during persistent ventricular fibrillation. Recognition system 3 notices the ventricular fibrillation at time 20 and immediately starts nerve stimulator 4 and the charging of capacitor 8. At the same time, checking system 5 checks that arrhythmia is present. Capacitor 8 will already be charged at time 21. At time 32 programmed for the emission of the shock, blanking circuit 7 protects the circuits with a signal of duration 24 which is greater than discharge time 22, stimulator 4 also being prevented for the period 23. Immediately afterwards, circuit 9 delivers shock 22 which should interrupt the ventricular fibrillation. Nerve stimulator 4 will continue to protect the patient from the pain for a programmable period which may be as long as a few minutes.
  • 62.FIG. 3B shows a case of ventricular fibrillation which disappears naturally at a time earlier than that programmed for the discharge. After the start at time 25 which triggers stimulator 4 and charging circuit 8, the ventricular fibrillation disappears at time 26, and all of the circuits are reset.
  • 63.FIG. 3C gives an example in which ventricular tachycardia occurs. At time 27, circuit 3 recognizes the type of arrhythmia as ventricular tachycardia and activates anti-arrhythmic stimulator circuit 10 which starts to deliver stimuli in accordance with the programmed algorithms.
  • 64. If these stimuli are effective, the ventricular tachycardia will be stopped and circuits 3 and 10 will be reset. If, however, the treatment with anti-arrhythmic stimulator circuit 10 is not effective, after the delivery of a certain number of programs (3-5 times in succession) circuit 3 will start both spinal cord stimulator (SCS) generator 4 and the capacitor-charging circuit 8 at time 28 up to the time at which the programmed energy 25 is reached. At the time 33, as in the case described in FIG. 3A, blanking signal 31 will start and will protect the circuits of the system during the shock for period 34. The delivery of shock 30 will cancel out the arrhythmia and the system will be reset.
  • 65.FIG. 4 shows the sequence of operation of the various blocks in the case of atrial fibrillation. Also this refers to FIG. 2.
  • 66. Recognition system 3 detects atrial fibrillation at time 40. At the same time, the charging of the capacitor by block 8 is started, the programmed energy being reached after time 46 which may even be one minute. At the same time, or at time 41 after the recognition of the atrial fibrillation, nerve stimulator 4 starts the stimulation. Checking system 5 checks the existence of atrial fibrillation.
  • 67. At time 42, a fraction of a second before the shock, the blocking of the blanking unit is switched on for time 45 which lasts until a few hundred milliseconds after the shock. During time 45, the circuits of blocks 3, 4 and 5 are prevented and/or protected against the shock energy which is propagated through the patient's body. During time 45, the cardioversion electric shock is delivered and is synchronized with the patient's QRS by blocks 3 and 5. Circuits 3 and 5 then become active again in order to monitor the patient and nerve stimulator 4 continues in accordance with the program setting.

Claims (25)

What is claimed is:
1. A method of electrically defibrillating a heart, comprising:
(a) sensing a heart arrhythmia;
(b) stimulating the spinal column to produce an analgesic effect; and
(c ) delivering an electrical shock to defibrillate the heart.
2. A method of electrically defibrillating a heart as in
claim 1
, wherein the step of stimulating the spinal column comprises saturating the pathways of the pain caused by the shock by the gate control method.
3. A method of electrically defibrillating a heart as in
claim 1
, wherein the step of delivering the electrical shock is synchronized with the patient's QRS.
4. A method of electrically defibrillating a heart as in
claim 1
, wherein a blanking circuit is provided, the blanking circuit generating a signal which can protect the other circuits from the electrical shock, the blanking circuit being activated prior to the delivery of the shock and termninating after delivery of the shock.
5. A method of electrically defibrillating a heart as in
claim 1
, wherein the arrhythma is a ventricular fibrillation.
6. A method of electrically defibrillating a heart as in
claim 5
, wherein the step of sensing the ventricular fibrillation comprises sensing within 2 seconds from the start of the ventricular fibrillation an electrical signal from the heart having an average frequency of greater than 280-300 beats per minute with irregularities in period and amplitude and sensing a stoppage of pumping of the heart.
7. A method of electrically defibrillating a heart as in
claim 5
, wherein the step of delivering the electrical shock comprises delivering the electrical shock no longer than three seconds after sensing the ventricular fibrillation.
8. A method of electrically defibrillating a heart as in
claim 5
, wherein the step of stimulating the spinal column to produce an analgesic effect comprises infusing an analgesic drug immediately upon sensing the ventricular fibrillation.
9. A method of electrically defibrillating a heart as in
claim 5
, wherein the step of stimulating the spinal column to produce an analgesic effect comprises electrically stimulating a nerve immediately upon sensing the ventricular fibrillation.
10. A method of electrically defibrillating a heart as in
claim 5
, wherein the step of stimulating the spinal column comprises saturating the pathways of the pain caused by the shock by the gate control method.
11. A method of electrically defibrillating a heart as in
claim 5
, wherein a blanking circuit is provided, the blanking circuit generating a signal which can protect the other circuits from the electrical shock, the blanking circuit being activated prior to the delivery of the shock and terminating after delivery of the shock.
12. A method of electrically defibrillating a heart as in
claim 1
, wherein the arrhythmia is an atrial arrhythmia.
13. A method of electrically defibrillating a heart as in
claim 12
, wherein the step of sensing the arrhythmia allows sufficient time to verify the stability of the arrhythmia.
14. A method of electrically defibrillating a heart as in
claim 12
, wherein the step of delivering the electrical shock may take up to one minute from sensing the arrhythmia, and the electrical shock is between 1 and 10 Joules.
15. A method of electrically defibrillating a heart as in
claim 12
, wherein the step of stimulating the spinal column occurs at least two seconds before the electrical shock.
16. A method of electrically defibrillating a heart as in
claim 12
, wherein the step of delivering the electrical shock is synchronized with the patient's QRS.
17. A method of electrically defibrillating a heart as in
claim 12
, wherein the step of stimulating the spinal column comprises saturating the pathways of the pain caused by the shock by the gate control method.
18. A method of electrically defibrillating a heart as in
claim 12
, wherein a blanking circuit is provided, the blanking circuit generating a signal which can protect the other circuits from the electrical shock, the blanking circuit being activated prior to the delivery of the shock and terminating after delivery of the shock.
19. A method of electrically defibrillating a heart as in
claim 1
, wherein the arrhythmia is ventricular tachycardia.
20. A method of electrically defibrillating a heart as in
claim 19
, wherein the step of sensing the ventricular tachycardia comprises sensing an electrical signal from the heart beating up to 300 beats per minutes, wherein the beats have substantially constant frequency and amplitude, and further sensing an attenuated and/or irregular blood flow without stoppage of the heart.
21. A method of electrically defibrillating a heart as in
claim 19
, further comprising the step of applying a pacing electrical stimulus as a first treatment and, if this is unsuccessful after a programmed number of attempts, delivering a low energy cardioversion shock.
22. A method of electrically defibrillating a heart as in
claim 19
, wherein the step of stimulating the spinal column comprises saturating the pathways of the pain caused by the shock by the gate control method.
23. A method of electrically defibrillating a heart as in
claim 19
, wherein a blanking circuit is provided, the blanking circuit generating a signal which can protect the other circuits from the electrical shock, the blanking circuit being activated prior to the delivery of the delivery of the shock and terminating after delivery of the shock.
24. A method of electrically defibrillating a heart as in
claim 1
, wherein the step of stimulating the spinal column comprises infusing an analgesic drug with immediate effect.
25. A method of electrically defibrillating a heart as in
claim 1
, wherein the step of sensing the arrhythmia comprises sensing the arrhythmia through electrical, mechanical, or electromechanical impulses.
US09/732,320 1997-04-08 2000-12-07 Implantable electric heart defibrillator with attenuation of the pain resulting from the electric shock Abandoned US20010001126A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US09/732,320 US20010001126A1 (en) 1997-04-08 2000-12-07 Implantable electric heart defibrillator with attenuation of the pain resulting from the electric shock
US10/357,833 US20030120312A1 (en) 1997-04-08 2003-02-04 Implantable electric heart defibrillator with attenuation of the pain resulting from the electric shock

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ITFI97A000071 1997-04-08
IT97FI000071A IT1291822B1 (en) 1997-04-08 1997-04-08 SYSTEM FOR IMPLANTABLE ELECTRIC CARDIAC DEFIBRILLATION WITH ATTENTION OF PAIN RESULTING FROM ELECTRIC SHOCK BY MEANS OF
US09/057,206 US6167305A (en) 1997-04-08 1998-04-08 Implantable electric heart defibrillation system with attenuation of the pain resulting from the electric shock
US09/732,320 US20010001126A1 (en) 1997-04-08 2000-12-07 Implantable electric heart defibrillator with attenuation of the pain resulting from the electric shock

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/057,206 Division US6167305A (en) 1997-04-08 1998-04-08 Implantable electric heart defibrillation system with attenuation of the pain resulting from the electric shock

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/357,833 Continuation US20030120312A1 (en) 1997-04-08 2003-02-04 Implantable electric heart defibrillator with attenuation of the pain resulting from the electric shock

Publications (1)

Publication Number Publication Date
US20010001126A1 true US20010001126A1 (en) 2001-05-10

Family

ID=11352028

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/057,206 Expired - Lifetime US6167305A (en) 1997-04-08 1998-04-08 Implantable electric heart defibrillation system with attenuation of the pain resulting from the electric shock
US09/732,320 Abandoned US20010001126A1 (en) 1997-04-08 2000-12-07 Implantable electric heart defibrillator with attenuation of the pain resulting from the electric shock
US10/357,833 Abandoned US20030120312A1 (en) 1997-04-08 2003-02-04 Implantable electric heart defibrillator with attenuation of the pain resulting from the electric shock

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/057,206 Expired - Lifetime US6167305A (en) 1997-04-08 1998-04-08 Implantable electric heart defibrillation system with attenuation of the pain resulting from the electric shock

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/357,833 Abandoned US20030120312A1 (en) 1997-04-08 2003-02-04 Implantable electric heart defibrillator with attenuation of the pain resulting from the electric shock

Country Status (3)

Country Link
US (3) US6167305A (en)
EP (1) EP0870518A1 (en)
IT (1) IT1291822B1 (en)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040088015A1 (en) * 2002-10-31 2004-05-06 Casavant David A. Respiratory nerve stimulation
WO2004041350A1 (en) * 2002-10-31 2004-05-21 Medtronic, Inc. Auxilary central nervous system pre-pulse for shock pain inhibition
US20040220628A1 (en) * 2003-04-11 2004-11-04 Wagner Darrell Orvin Subcutaneous defibrillation timing correlated with induced skeletal muscle contraction
US20040230230A1 (en) * 2003-04-11 2004-11-18 Lindstrom Curtis Charles Methods and systems involving subcutaneous electrode positioning relative to a heart
WO2004110554A1 (en) * 2003-05-20 2004-12-23 Biotronik Gmbh & Co. Kg Implantable electric therapy device
US20070135847A1 (en) * 2005-12-12 2007-06-14 Kenknight Bruce H Subcutaneous defibrillation system and method using same
US20090156854A1 (en) * 2004-02-05 2009-06-18 Idemitsu Kosan Co., Ltd. Adamantane derivatives and process for producing the same
US20100114217A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Therapy system including cardiac rhythm therapy and neurostimulation capabilities
US20100114224A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US20100114205A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Shunt-current reduction housing for an implantable therapy system
US20100114189A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Therapy module crosstalk mitigation
US20100114198A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US20100114196A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US20100114202A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US20100114260A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Implantable therapeutic nerve stimulator
US20100114211A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Shunt-current reduction techniques for an implantable therapy system
US20100114258A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Isolation of sensing and stimulation circuitry
US20100114199A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US20100114200A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US20100114209A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Communication between implantable medical devices
US20100114216A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Interference mitigation for implantable device recharging
US20100114197A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US20100114208A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US20100114203A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US20100114241A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Interference mitigation for implantable device recharging
US20100114201A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US20100114248A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Isolation of sensing and stimulation circuitry
US9289613B2 (en) 2008-10-31 2016-03-22 Medtronic, Inc. Interdevice impedance
US9814886B2 (en) 2009-01-30 2017-11-14 Medtronic, Inc. Detecting and treating electromechanical dissociation of the heart

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8036741B2 (en) 1996-04-30 2011-10-11 Medtronic, Inc. Method and system for nerve stimulation and cardiac sensing prior to and during a medical procedure
IT1291822B1 (en) * 1997-04-08 1999-01-21 Leonardo Cammilli SYSTEM FOR IMPLANTABLE ELECTRIC CARDIAC DEFIBRILLATION WITH ATTENTION OF PAIN RESULTING FROM ELECTRIC SHOCK BY MEANS OF
US6772007B1 (en) 1997-05-14 2004-08-03 Pacesetter, Inc. System and method of generating a low-pain multi-step defibrillation waveform for use in an implantable cardioverter/defibrillator (ICD)
US6134470A (en) * 1998-11-09 2000-10-17 Medtronic, Inc. Method and apparatus for treating a tachyarrhythmic patient
US6650943B1 (en) 2000-04-07 2003-11-18 Advanced Bionics Corporation Fully implantable neurostimulator for cavernous nerve stimulation as a therapy for erectile dysfunction and other sexual dysfunction
US6487446B1 (en) * 2000-09-26 2002-11-26 Medtronic, Inc. Method and system for spinal cord stimulation prior to and during a medical procedure
US7386344B2 (en) * 2004-08-11 2008-06-10 Cardiac Pacemakers, Inc. Pacer with combined defibrillator tailored for bradycardia patients
US6751502B2 (en) 2001-03-14 2004-06-15 Cardiac Pacemakers, Inc. Cardiac rhythm management system with defibrillation threshold prediction
US6885895B1 (en) 2001-04-26 2005-04-26 Advanced Bionics Corporation Methods and systems for electrical and/or drug stimulation as a therapy for erectile dysfunction
US6928320B2 (en) * 2001-05-17 2005-08-09 Medtronic, Inc. Apparatus for blocking activation of tissue or conduction of action potentials while other tissue is being therapeutically activated
US6804554B2 (en) * 2001-10-19 2004-10-12 Medtronic, Inc. Arrangement and system for enabling patient control of electrical therapies
US6728574B2 (en) 2001-10-19 2004-04-27 Medtronic, Inc. System and method for patient-controlled relief of pain associated with electrical therapies
US20030163166A1 (en) * 2002-02-27 2003-08-28 Sweeney James D. Implantable defibrillator design with optimized multipulse waveform delivery and method for using
US20040106954A1 (en) * 2002-11-15 2004-06-03 Whitehurst Todd K. Treatment of congestive heart failure
US7566318B2 (en) 2003-04-11 2009-07-28 Cardiac Pacemakers, Inc. Ultrasonic subcutaneous dissection tool incorporating fluid delivery
US7702399B2 (en) 2003-04-11 2010-04-20 Cardiac Pacemakers, Inc. Subcutaneous electrode and lead with phoresis based pharmacological agent delivery
US7529592B2 (en) 2003-04-11 2009-05-05 Cardiac Pacemakers, Inc. Subcutaneous electrode and lead with temporary pharmacological agents
US7164944B1 (en) 2003-04-15 2007-01-16 Pacesetter, Inc. Analgesic therapy for ICD patients
US20070083240A1 (en) * 2003-05-08 2007-04-12 Peterson David K L Methods and systems for applying stimulation and sensing one or more indicators of cardiac activity with an implantable stimulator
US7181276B1 (en) 2004-07-27 2007-02-20 Pacesetter, Inc. Device and method for preventing the acceleration of cardiac arrhythmias
US7308305B1 (en) 2004-07-27 2007-12-11 Pacesetter, Inc. Optimally timed early shock defibrillation
US7277755B1 (en) 2004-09-08 2007-10-02 Pacesetter, Inc. Subcutaneous cardiac stimulation device providing anti-tachycardia pacing therapy and method
US7386342B1 (en) * 2004-09-08 2008-06-10 Pacesetter, Inc. Subcutaneous cardiac stimulation device providing anti-tachycardia pacing therapy and method
US7260433B1 (en) 2004-09-08 2007-08-21 Pacesetter, Inc. Subcutaneous cardiac stimulation device providing anti-tachycardia pacing therapy and method
US7894896B2 (en) * 2005-05-13 2011-02-22 Cardiac Pacemakers, Inc. Method and apparatus for initiating and delivering cardiac protection pacing
US20070073354A1 (en) 2005-09-26 2007-03-29 Knudson Mark B Neural blocking therapy
US8027718B2 (en) * 2006-03-07 2011-09-27 Mayo Foundation For Medical Education And Research Regional anesthetic
US7941214B2 (en) * 2006-03-29 2011-05-10 Medtronic, Inc. Method and apparatus for detecting arrhythmias in a subcutaneous medical device
US7742812B2 (en) 2006-03-29 2010-06-22 Medtronic, Inc. Method and apparatus for detecting arrhythmias in a medical device
US7643876B2 (en) * 2006-08-31 2010-01-05 Cardiac Pacemakers, Inc. System and method to reduce device therapy pain
US8706212B2 (en) * 2006-12-13 2014-04-22 Cardiac Pacemakers, Inc. Neural stimulation systems, devices and methods
US7890167B2 (en) * 2007-04-03 2011-02-15 Cardiac Pacemakers, Inc. Pain free defibrillation threshold estimation
AU2012200603B2 (en) * 2007-09-25 2013-07-11 Cardiac Pacemakers, Inc. Neurostimulation systems for cardiac conditions
US20090204173A1 (en) 2007-11-05 2009-08-13 Zi-Ping Fang Multi-Frequency Neural Treatments and Associated Systems and Methods
US8255057B2 (en) 2009-01-29 2012-08-28 Nevro Corporation Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions
AU2010238752B2 (en) 2009-04-22 2014-05-29 Nevro Corporation Spinal cord modulation for inducing paresthetic and anesthetic effects, and associated systems and methods
DE202010018338U1 (en) 2009-04-22 2015-10-12 Nevro Corporation Spinal cord modulation system for the relief of chronic pain
US8406868B2 (en) 2010-04-29 2013-03-26 Medtronic, Inc. Therapy using perturbation and effect of physiological systems
US8620425B2 (en) 2010-04-29 2013-12-31 Medtronic, Inc. Nerve signal differentiation in cardiac therapy
US8639327B2 (en) 2010-04-29 2014-01-28 Medtronic, Inc. Nerve signal differentiation in cardiac therapy
US8718763B2 (en) 2011-01-19 2014-05-06 Medtronic, Inc. Vagal stimulation
US8781583B2 (en) 2011-01-19 2014-07-15 Medtronic, Inc. Vagal stimulation
US8725259B2 (en) 2011-01-19 2014-05-13 Medtronic, Inc. Vagal stimulation
US8706223B2 (en) 2011-01-19 2014-04-22 Medtronic, Inc. Preventative vagal stimulation
US8781582B2 (en) 2011-01-19 2014-07-15 Medtronic, Inc. Vagal stimulation
US9775559B2 (en) 2013-04-26 2017-10-03 Medtronic, Inc. Staged rhythm detection system and method
US9526908B2 (en) 2014-04-01 2016-12-27 Medtronic, Inc. Method and apparatus for discriminating tachycardia events in a medical device
US10376705B2 (en) 2014-04-01 2019-08-13 Medtronic, Inc. Method and apparatus for discriminating tachycardia events in a medical device
US9808640B2 (en) 2014-04-10 2017-11-07 Medtronic, Inc. Method and apparatus for discriminating tachycardia events in a medical device using two sensing vectors
US9352165B2 (en) 2014-04-17 2016-05-31 Medtronic, Inc. Method and apparatus for verifying discriminating of tachycardia events in a medical device having dual sensing vectors
US10278601B2 (en) 2014-04-24 2019-05-07 Medtronic, Inc. Method and apparatus for selecting a sensing vector configuration in a medical device
US10244957B2 (en) 2014-04-24 2019-04-02 Medtronic, Inc. Method and apparatus for selecting a sensing vector configuration in a medical device
US9795312B2 (en) 2014-04-24 2017-10-24 Medtronic, Inc. Method and apparatus for adjusting a blanking period for selecting a sensing vector configuration in a medical device
US10252067B2 (en) 2014-04-24 2019-04-09 Medtronic, Inc. Method and apparatus for adjusting a blanking period during transitioning between operating states in a medical device
US9610025B2 (en) 2014-07-01 2017-04-04 Medtronic, Inc. Method and apparatus for verifying discriminating of tachycardia events in a medical device having dual sensing vectors
US9770599B2 (en) * 2014-08-12 2017-09-26 Cyberonics, Inc. Vagus nerve stimulation and subcutaneous defibrillation system
US10188867B2 (en) 2015-01-23 2019-01-29 Medtronic, Inc. Method and apparatus for beat acquisition during template generation in a medical device having dual sensing vectors
US9561005B2 (en) 2015-01-23 2017-02-07 Medtronic, Inc. Method and apparatus for beat acquisition during template generation in a medical device having dual sensing vectors
US11318310B1 (en) 2015-10-26 2022-05-03 Nevro Corp. Neuromodulation for altering autonomic functions, and associated systems and methods
EP3578124A1 (en) * 2018-06-05 2019-12-11 National University of Ireland Galway Electrophysiology apparatus
US11590352B2 (en) 2019-01-29 2023-02-28 Nevro Corp. Ramped therapeutic signals for modulating inhibitory interneurons, and associated systems and methods

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1000030A1 (en) * 1980-02-28 1983-02-28 Научно-Производственное Объединение По Радиоэлектронной Медицинской Аппаратуре "Рэма" Defibriller
US4830006B1 (en) * 1986-06-17 1997-10-28 Intermedics Inc Implantable cardiac stimulator for detection and treatment of ventricular arrhythmias
US4984572A (en) * 1988-08-18 1991-01-15 Leonard Bloom Hemodynamically responsive system for and method of treating a malfunctioning heart
US5058583A (en) * 1990-07-13 1991-10-22 Geddes Leslie A Multiple monopolar system and method of measuring stroke volume of the heart
IT1245814B (en) 1991-05-21 1994-10-18 Sorin Biomedica Spa RATE RESPONSIVE CARDIOSTIMULATOR DEVICE
US5213098A (en) * 1991-07-26 1993-05-25 Medtronic, Inc. Post-extrasystolic potentiation stimulation with physiologic sensor feedback
US5205283A (en) * 1991-07-30 1993-04-27 Medtronic, Inc. Method and apparatus for tachyarrhythmia detection and treatment
US5370667A (en) * 1992-04-03 1994-12-06 Intermedics, Inc. Device and method for automatically adjusting tachycardia recognition criteria based on detected parameter
IT1256900B (en) 1992-07-27 1995-12-27 Franco Vallana PROCEDURE AND DEVICE TO DETECT CARDIAC FUNCTIONALITY.
US5318591A (en) * 1992-11-23 1994-06-07 Siemens Pacesetter, Inc. Implantable cardioverter-defibrillator having early charging capability
US5620464A (en) * 1992-12-18 1997-04-15 Angeion Corporation System and method for delivering multiple closely spaced defibrillation pulses
US5792187A (en) * 1993-02-22 1998-08-11 Angeion Corporation Neuro-stimulation to control pain during cardioversion defibrillation
US5423883A (en) * 1993-07-14 1995-06-13 Pacesetter, Inc. Implantable myocardial stimulation lead with sensors thereon
IT1260692B (en) 1993-10-05 1996-04-22 Sorin Biomedica Spa DEVICE FOR DETERMINING THE MYOCARDIC FUNCTION AND ITS PROCEDURE.
IT1280992B1 (en) 1995-10-20 1998-02-11 Sorin Biomedica Cardio Spa IMPROVEMENTS IN DEVICES FOR DETERMINING MYOCARDIAL FUNCTION AND RELATED PROCEDURE.
US5662689A (en) * 1995-09-08 1997-09-02 Medtronic, Inc. Method and apparatus for alleviating cardioversion shock pain
IT1281054B1 (en) 1995-12-05 1998-02-11 Sorin Biomedica Cardio Spa CARDIAC STIMULATOR DEVICE WITH VARIABLE PACING FREQUENCY
IT1291822B1 (en) * 1997-04-08 1999-01-21 Leonardo Cammilli SYSTEM FOR IMPLANTABLE ELECTRIC CARDIAC DEFIBRILLATION WITH ATTENTION OF PAIN RESULTING FROM ELECTRIC SHOCK BY MEANS OF

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040088015A1 (en) * 2002-10-31 2004-05-06 Casavant David A. Respiratory nerve stimulation
WO2004041350A1 (en) * 2002-10-31 2004-05-21 Medtronic, Inc. Auxilary central nervous system pre-pulse for shock pain inhibition
US7277757B2 (en) * 2002-10-31 2007-10-02 Medtronic, Inc. Respiratory nerve stimulation
US20040220628A1 (en) * 2003-04-11 2004-11-04 Wagner Darrell Orvin Subcutaneous defibrillation timing correlated with induced skeletal muscle contraction
US20040230230A1 (en) * 2003-04-11 2004-11-18 Lindstrom Curtis Charles Methods and systems involving subcutaneous electrode positioning relative to a heart
WO2004110554A1 (en) * 2003-05-20 2004-12-23 Biotronik Gmbh & Co. Kg Implantable electric therapy device
US20090156854A1 (en) * 2004-02-05 2009-06-18 Idemitsu Kosan Co., Ltd. Adamantane derivatives and process for producing the same
US20070135847A1 (en) * 2005-12-12 2007-06-14 Kenknight Bruce H Subcutaneous defibrillation system and method using same
US20100114217A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Therapy system including cardiac rhythm therapy and neurostimulation capabilities
US20100114224A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US20100114205A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Shunt-current reduction housing for an implantable therapy system
US20100114189A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Therapy module crosstalk mitigation
US20100114198A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US20100114221A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Therapy system including cardiac rhythm therapy and neurostimulation capabilities
US20100114196A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US20100114202A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US20100114260A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Implantable therapeutic nerve stimulator
US20100114211A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Shunt-current reduction techniques for an implantable therapy system
US20100114258A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Isolation of sensing and stimulation circuitry
US20100114199A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US20100114200A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US20100114209A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Communication between implantable medical devices
US20100114216A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Interference mitigation for implantable device recharging
US20100114197A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US20100114208A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US20100114203A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US20100114241A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Interference mitigation for implantable device recharging
US20100114201A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US20100114248A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Isolation of sensing and stimulation circuitry
US8005539B2 (en) 2008-10-31 2011-08-23 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US8249708B2 (en) 2008-10-31 2012-08-21 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US8260412B2 (en) 2008-10-31 2012-09-04 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US8265771B2 (en) 2008-10-31 2012-09-11 Medtronic, Inc. Interference mitigation for implantable device recharging
US8301263B2 (en) 2008-10-31 2012-10-30 Medtronic, Inc. Therapy module crosstalk mitigation
US8406893B2 (en) 2008-10-31 2013-03-26 Medtronic, Inc. Interference mitigation for implantable device recharging
US8452394B2 (en) 2008-10-31 2013-05-28 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US8473057B2 (en) 2008-10-31 2013-06-25 Medtronic, Inc. Shunt-current reduction housing for an implantable therapy system
US8498698B2 (en) 2008-10-31 2013-07-30 Medtronic, Inc. Isolation of sensing and stimulation circuitry
US8527045B2 (en) 2008-10-31 2013-09-03 Medtronic, Inc. Therapy system including cardiac rhythm therapy and neurostimulation capabilities
US8532779B2 (en) 2008-10-31 2013-09-10 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US8560060B2 (en) 2008-10-31 2013-10-15 Medtronic, Inc. Isolation of sensing and stimulation circuitry
US8612020B2 (en) 2008-10-31 2013-12-17 Medtronic, Inc. Implantable therapeutic nerve stimulator
US8611996B2 (en) 2008-10-31 2013-12-17 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US8688210B2 (en) 2008-10-31 2014-04-01 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US8774918B2 (en) 2008-10-31 2014-07-08 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US9026206B2 (en) 2008-10-31 2015-05-05 Medtronic, Inc. Therapy system including cardiac rhythm therapy and neurostimulation capabilities
US9192769B2 (en) 2008-10-31 2015-11-24 Medtronic, Inc. Shunt-current reduction techniques for an implantable therapy system
US9289613B2 (en) 2008-10-31 2016-03-22 Medtronic, Inc. Interdevice impedance
US9597505B2 (en) 2008-10-31 2017-03-21 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US9775987B2 (en) 2008-10-31 2017-10-03 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US9814886B2 (en) 2009-01-30 2017-11-14 Medtronic, Inc. Detecting and treating electromechanical dissociation of the heart

Also Published As

Publication number Publication date
US20030120312A1 (en) 2003-06-26
IT1291822B1 (en) 1999-01-21
US6167305A (en) 2000-12-26
ITFI970071A1 (en) 1998-10-08
EP0870518A1 (en) 1998-10-14
ITFI970071A0 (en) 1997-04-08

Similar Documents

Publication Publication Date Title
US6167305A (en) Implantable electric heart defibrillation system with attenuation of the pain resulting from the electric shock
US6298267B1 (en) Method and apparatus for treatment of cardiac electromechanical dissociation
EP0850088B1 (en) Apparatus for alleviating cardioversion shock pain
US6259949B1 (en) Method and apparatus for treatment of cardiac electromechanical dissociation
US6611713B2 (en) Implantable device for diagnosing and distinguishing supraventricular and ventricular tachycardias
US5620468A (en) Method and apparatus for treatment of atrial fibrillation
US5181511A (en) Apparatus and method for antitachycardia pacing using a virtual electrode
US5014698A (en) Method of and system for monitoring and treating a malfunctioning heart
EP2081643B1 (en) System for neurally-mediated anti-arrhythmic therapy
US7089055B2 (en) Method and apparatus for delivering pre-shock defibrillation therapy
US6526317B2 (en) System and method for treating atrial arrhythmias
US7421294B2 (en) System and method for preventing recurrence of atrial tachyarrhythmia
US20100057153A1 (en) Electromagnetic interference alarm
US7386343B1 (en) Spectrum-driven arrhythmia treatment method
US7164944B1 (en) Analgesic therapy for ICD patients
Newman et al. Permanent antitachycardia pacemaker therapy for ventricular tachycardia
US20230098220A1 (en) Cardiac rhythm management system and method
WO2023030921A1 (en) Implantable system and method for providing anti-tachycardia and/or shock therapy
WO2023030913A1 (en) Implantable system and method for providing anti-tachycardia and/or shock therapy
CN117836033A (en) Implantable systems and methods for providing anti-tachycardia and/or shock therapy
De Belder et al. Implantable electrical devices in the management of tachyarrhythmias

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION